Substantiating the concerns about recombinant human activated protein C use in sepsis

被引：16

作者：

Deans, KJ ^{[1
]}

Minneci, PC ^{[1
]}

Banks, SM ^{[1
]}

Natanson, C ^{[1
]}

Eichacker, PQ ^{[1
]}

机构：

[1] NIH, Warren Grant Magnuson Clin Ctr, Dept Crit Care Med, Bethesda, MD 20892 USA

来源：

CRITICAL CARE MEDICINE | 2004年 / 32卷 / 12期

关键词：

activated protein C; drotrecogin alfa; PROWESS; mortality; recombinant human activated protein C; corticosteroids; clinical practice;

D O I：

10.1097/01.CCM.0000148090.94378.6A

中图分类号：

R4 [临床医学];

学科分类号：

1002 [临床医学]; 100602 [中西医结合临床];

摘要：

引用

页码：2542 / 2543

页数：2

共 8 条

[1]

Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis [J].

Annane, D ;

Bellissant, E ;

Bollaert, PE ;

Briegel, J ;

Keh, D ;

Kupfer, Y .

BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7464) :480-484

[2]

[Anonymous], FDA Briefing Document: Johnson & Johnson/Janssen COVID-19 Vaccine

[3]

Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].

Bernard, GR ;

Vincent, JL ;

Laterre, P ;

LaRosa, SP ;

Dhainaut, JF ;

Lopez-Rodriguez, A ;

Steingrub, JS ;

Garber, GE ;

Helterbrand, JD ;

Ely, EW ;

Fisher, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709

[4]

Risk and the efficacy of antiinflammatory agents - Retrospective and confirmatory studies of sepsis [J].

Eichacker, PQ ;

Parent, C ;

Kalil, A ;

Esposito, C ;

Cui, X ;

Banks, SM ;

Gerstenberger, EP ;

Fitz, Y ;

Danner, RL ;

Natanson, C .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (09) :1197-1205

[5]

Sources of variability on the estimate of treatment effect in the PROWESS trial: Implications for the design and conduct of future studies in severe sepsis [J].

Macias, WL ;

Vallet, B ;

Bernard, GR ;

Vincent, JL ;

Laterre, PF ;

Nelson, DR ;

Derchak, A ;

Dhainaut, JF .

CRITICAL CARE MEDICINE, 2004, 32 (12) :2385-2391

[6]

Meta-analysis: The effect of steroids on survival and shock during sepsis depends on the dose [J].

Minneci, PC ;

Deans, KJ ;

Banks, SM ;

Eichacker, PQ ;

Natanson, C .

ANNALS OF INTERNAL MEDICINE, 2004, 141 (01) :47-56

[7]

TANZI M, 2004, USE DROTRECOGIN ALFA

[8]

Risks and benefits of activated protein C treatment for severe sepsis. [J].

Warren, HS ;

Suffredini, AF ;

Eichacker, PQ ;

Munford, RS .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :1027-1030

← 1 →